Who is pharmaxis ltd? Pharmaxis Ltd is an Australian pharmaceutical research company and a global leader in drug development for inflammation and fibrotic diseases. The company has a highly productive drug discovery engine, drug candidates in clinical trials and significant future cash flows from partnering deals.Does pharmaxis have a drug for bone cancer? Read more here. Pharmaxis is advancing a 6-month Phase 2 clinical trial of a new drug (PXS-5505) targeting the rare bone cancer myelofibrosis (MF).How much are pharmaxis shares worth? Shares in Pharmaxis are currently trading at A$0.095, giving the company a market capitalisation of £20.8m. Where are Pharmaxis shares listed? Where are Pharmaxis shares listed? What kind of share is Pharmaxis? Based on an overall assessment of its quality, value and momentum, Pharmaxis is currently classified as a Style Neutral.Whats new at pharmaxis and charlie teo? Recent Highlights Pharmaxis and Charlie Teo Foundation Identify Promising New Drug to Tackle Brain Cancer An Australian drug discovery will be the focus of a new study to tackle an aggressive and deadly form of brain cancer with a funding grant from the Charlie Teo Foundation.
Pharmaxis. Frequently Asked Questions. When was Pharmaxis founded?. Pharmaxis was founded in 1998.. Who are Pharmaxis key executives?. Pharmaxis's key executives are Edward J. Rayner, Malcolm J McComas and Will Delaat.. How many employees does Pharmaxis have?. Pharmaxis has 69 employees.. Who are Pharmaxis competitors?. ...